MedGenome Celebrates A Decade Of Leading Genomics In India

MedGenome, a leader in genomics-driven diagnostics and research, marks its tenth anniversary, celebrating a decade of transformative contributions to healthcare. Since its founding in 2013, the company has played a pivotal role in integrating genomics into clinical practice, significantly improving health outcomes for millions.

In a press statement on Wednesday, the company informed that in order to commemorate the occasion, MedGenome has released a corporate video titled 10 Years of Pioneering Genomics. The film showcases the company’s decade-long journey, honoring the dedication of its partners, investors, clinicians, scientists, bioinformaticians, lab technicians, and over 1,100 employees who have worked tirelessly to advance science and technology. Through the hashtag #10yearsofpioneeringgenomics, MedGenome reaffirms its commitment to making quality and affordable genetic solutions accessible to all sections of society.

Since its inception, MedGenome has introduced over 1,300 genetic tests in India, spanning fields such as oncology, inherited diseases, reproductive health, infectious diseases, and preventive wellness. Some of the company’s key innovations include Non-Invasive Prenatal Testing (NIPT), liquid biopsy for cancer (OncoTrack), and whole genome sequencing for drug-resistant TB strains.

In addition to its diagnostic advancements, MedGenome has sequenced over 350,000 exomes and genomes, contributing to international research efforts, including the GenomeAsia 100K initiative to sequence 100,000 South Asian genomes. The company has collaborated with more than 5,500 hospitals and 15,000 clinicians across India, making genetic testing more accessible nationwide.

MedGenome’s global expansion has been supported by key acquisitions, including its recent majority stake in Odisha-based GenX Diagnostics and its acquisition of Delhi-NCR-based Prognosis Laboratories. These strategic moves have strengthened the company’s presence in Tier 2 and Tier 3 cities, ensuring wider access to genetic testing services in underserved regions.

Looking to the future, MedGenome aims to deepen its focus on multi-omics research to better understand biological systems and mechanisms. The company also plans to continue expanding its reach through mergers and acquisitions, addressing the growing global demand for affordable genomic solution.